![](/images/2.png)
- Details
- Written by: Dhaval Gupta
- Category: Perspectives
- Hits: 360
![](/images/3.png#joomlaImage://local-images/3.png)
- Details
- Written by: Dhaval Gupta
- Category: Perspectives
- Hits: 334
![Image for Revolutionizing Treatment: Gain Therapeutics Leads the Way in AI-Driven Drug Discovery for Complex Diseases](/images/pexels-tara-winstead-8386440-1-2048x1152.jpg#joomlaImage://local-images/pexels-tara-winstead-8386440-1-2048x1152.jpg)
- Details
- Written by: Developer SM
- Category: Perspectives
- Hits: 900
What Makes a Truly Valuable AI Drug Discovery Platform?
The value in AI drug discovery platforms lies in their ability to target known, yet previously unreachable, therapeutic targets. Gain Therapeutics’ Magellan™ exemplifies this by combining AI with a physics-based approach to identify novel allosteric binding sites on disease-implicated proteins.
![Image for Revolutionizing Treatment: Gain Therapeutics Leads the Way in AI-Driven Drug Discovery for Complex Diseases](/images/perspectives/thumbnails/kol.jpg)
- Details
- Written by: Developer SM
- Category: Perspectives
- Hits: 446
Gain Therapeutics is ready to share the latest R&D update on Parkinson’s Disease. This event is intended for all KOL’s, Analysts, Patient Advocates, and investors who share a common interest in neurodegenerative diseases.
“Beyond Symptomatic Treatment of #Parkinson’s Disease: Gain Therapeutics R&D Update with KOL & Analyst Insights 2024”
This R&D update event will occur Thursday, February 22nd, 2024 between 11:00 am – 12:00 pm EST.
Registration information can be found here: https://lnkd.in/erx-c4vn
Participants are encouraged to send questions to
Discussion Topics will include:
![Image for Revolutionizing Treatment: Gain Therapeutics Leads the Way in AI-Driven Drug Discovery for Complex Diseases](/images/cover.jpg)
- Details
- Written by: Developer SM
- Category: Perspectives
- Hits: 637
Beatriz Calvo-Flores Guzman, presented at the 20th Annual WORLDSymposium discussing preclinical data demonstrating that our clinical-stage GCase regulator provided neuroprotection & restored motor function in Parkinson’s disease models following delayed administration.
![Novel Treatment for Parkinson’s Advancing Through Phase 1 Clinical Trials](/images/perspectives/thumbnails/1280-720.png)
- Details
- Written by: Developer SM
- Category: Perspectives
- Hits: 656
Novel Treatment for Parkinson’s Advancing Through Phase 1 Clinical Trials
![](/images/perspectives/thumbnails/beyong.jpg)
- Details
- Written by: Designer SM
- Category: Perspectives
- Hits: 500
Gain Therapeutics will be attending JP Morgan HealthCare Conference Jan 8th to 11th, 2024 in San Francisco.
![Image for Revolutionizing Treatment: Gain Therapeutics Leads the Way in AI-Driven Drug Discovery for Complex Diseases](/images/a1.jpg#joomlaImage://local-images/a1.jpg)
- Details
- Written by: Developer SM
- Category: Perspectives
- Hits: 427
![Novel Treatment for Parkinson’s Advancing Through Phase 1 Clinical Trials](/images/WhatsApp-Image-2023-10-20-at-06.51.32_1f902ab6.jpg#joomlaImage://local-images/WhatsApp-Image-2023-10-20-at-06.51.32_1f902ab6.jpg)
- Details
- Written by: Developer SM
- Category: Perspectives
- Hits: 744
![Image for Revolutionizing Treatment: Gain Therapeutics Leads the Way in AI-Driven Drug Discovery for Complex Diseases](/images/Mathias-Alder.jpg#joomlaImage://local-images/Mathias-Alder.jpg)
- Details
- Written by: Developer SM
- Category: Perspectives
- Hits: 626
![Image for Revolutionizing Treatment: Gain Therapeutics Leads the Way in AI-Driven Drug Discovery for Complex Diseases](/images/perspectives/thumbnails/MND-research-768x432.png)
- Details
- Written by: Developer SM
- Category: Perspectives
- Hits: 447